Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3616
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Ventavis (Solution)
|
| dailymed-instance:dosage |
Ventavis is intended to be inhaled using either of two pulmonary
drug delivery devices: the I-neb���AAD
System or the Prodose AAD
System. The first inhaled dose should be 2.5 mcg (as delivered at the
mouthpiece). If this dose is well tolerated, dosing should be increased
to 5.0 mcg and maintained at that dose; otherwise maintain the dose at
2.5 mcg. Ventavis should be taken 6 to 9 times per day (no more than
once every 2 hours) during waking hours, according to individual need
and tolerability. The maximum daily dose evaluated in clinical studies
was 45 mcg (5 mcg 9 times per day). Direct mixing of Ventavis with other medications in the
I-neb���AAD System or
Prodose AAD System has not
been evaluated. To avoid potential interruptions in drug delivery due to equipment malfunctions, the patient should have easy access to a back-up
I-neb���AAD System or
Prodose AAD System. Ventavis is supplied in two ampule configurations, a 2 mL and 1
mL single-use glass ampule. Both ampule sizes contain 10 mcg/1 mL. The 2 mL single-use ampule delivers 20 mcg to the medication
chamber of either of the AAD Delivery Systems. The
2 mL must be used with the Prodose
AAD System and may be used with the
I-neb���AAD System. The 1 mL ampule delivers 10 mcg to the medication chamber and
must only be used with the I-neb���AAD
System. Both the 2 mL and the 1 mL ampules deliver a nominal dose of
either 2.5 mcg or 5.0 mcg at the mouthpiece of the
AAD Delivery System for which they are labeled for
use. Each inhalation treatment requires one single-use ampule. For each inhalation session, the entire contents of one opened
ampule of Ventavis should be transferred into either the
I-neb���AAD System or the
Prodose AAD System
medication chamber (2 mL ampule only) immediately before use. After each
inhalation session, any solution remaining in the medication chamber
should be discarded. Use of the remaining solution will result in
unpredictable dosing. Patients should follow the
manufacturer's instructions for cleaning the I-neb���AAD System or the Prodose
AAD System components after each dose
administration.<br/>Preparation: Should patients deteriorate on this treatment,
alternative treatments should be considered. Several patients
whose status deteriorated while on Ventavis were successfully
switched to intravenous epoprostenol.<br/>Dosage and Administration in Hepatic Impairment: Because iloprost elimination is reduced in patients with
impaired liver function , caution should be exercised during iloprost therapy
in patients with at least Child Pugh Class B hepatic
impairment.<br/>Dosage and Administration in Renal Impairment: Dose adjustment is not required in patients not on
dialysis. The effect of dialysis on iloprost is unknown. Use
caution in treating patients on dialysis .
|
| dailymed-instance:activeIng... | |
| dailymed-instance:genericDr... | |
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:genericMe... |
iloprost
|
| dailymed-instance:fullName |
Ventavis (Solution)
|
| dailymed-instance:indicatio... |
Ventavis is indicated for the treatment of pulmonary arterial
hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms. In controlled trials, it improved a composite endpoint
consisting of exercise tolerance, symptoms (NYHA Class), and lack of
deterioration (see CLINICAL
PHARMACOLOGY, Clinical Trials).
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Ventavis
|